---
document_datetime: 2025-12-02 05:01:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/jinarc.html
document_name: jinarc.html
version: success
processing_time: 0.1184274
conversion_datetime: 2025-12-25 04:13:17.5138
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Jinarc

[RSS](/en/individual-human-medicine.xml/66801)

##### Authorised

This medicine is authorised for use in the European Union

tolvaptan Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Jinarc](#news-on)
- [More information on Jinarc](#more-information-on-jinarc-784)
- [More information on Jinarc](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Jinarc is a medicine used to treat adults with autosomal dominant polycystic kidney disease. This is an inherited condition in which numerous fluid-filled cysts develop in the kidneys, which eventually affect kidney function and can cause the kidneys to fail. Jinarc is for use in patients with normal to moderately reduced kidney function at the beginning of treatment with Jinarc and whose disease is progressing rapidly.

Jinarc contains the active substance tolvaptan.

Expand section

Collapse section

## How is Jinarc used?

Jinarc can only be obtained with a prescription and treatment must be started and monitored by a doctor experienced in treating autosomal dominant polycystic kidney disease and with knowledge about the risks of treatment with Jinarc.

Jinarc is available as tablets (15, 30, 45, 60 and 90 mg). It is taken twice a day in two unequal doses. Patients should be started with a dose of 45 mg in the morning and 15 mg in the evening (45+15 mg), and the dose should then be increased to 60+30 mg or 90+30 mg, depending on what the patient can tolerate. The morning dose should be taken at least 30 minutes before the morning meal, whereas the evening dose can be taken with or without food. Doses may need to be reduced in patients taking certain other medicines. Patients should drink plenty of water while on treatment.

For more information about using Jinarc, see the package leaflet or contact your doctor or pharmacist.

## How does Jinarc work?

The active substance in Jinarc, tolvaptan, is a vasopressin-2-receptor antagonist: it blocks receptors (targets) in the kidneys to which the hormone vasopressin attaches. Vasopressin regulates the level of water and sodium in the body. In autosomal dominant polycystic kidney disease, it is thought that kidney cells do not respond normally to vasopressin, leading to the formation of fluid-filled cysts. By blocking vasopressin receptors in the kidneys, Jinarc can slow down cyst formation.

## What benefits of Jinarc have been shown in studies?

Jinarc was shown to be effective at slowing down cyst formation in a main study involving 1,445 adults with autosomal dominant polycystic kidney disease who had rapidly progressing disease but normal or moderately reduced kidney function. In the study, Jinarc was compared with placebo (a dummy treatment) and the main measure of effectiveness was the change in kidney size after 3 years of treatment (a way of measuring the swelling caused by cyst formation). In patients taking placebo, the total size of the kidneys increased by 18.8% whereas in those taking Jinarc the increase was 9.6%. The effects of treatment were greatest in the first year. Subsequent supportive results confirmed that increase in kidney size over 5 years was slower with Jinarc.

## What are the risks associated with Jinarc?

The most common side effects with Jinarc (which may affect more than 2 in 10 people) are thirst, polyuria (increase in urine production), nocturia (need to pass urine at night) and pollakiuria (increased need to pass urine during the day). Jinarc may increase blood levels of certain liver enzymes (a sign of possible liver problems). For the full list of all side effects reported with Jinarc, see the package leaflet.

Jinarc must not be started in certain patients with increased blood levels of liver enzymes or with signs or symptoms of liver injury. Blood tests to check the patient's liver function should be performed before starting treatment with Jinarc, and then repeated every month for 18 months and every three months thereafter. Patients should also be monitored for symptoms of liver injury (such as loss of appetite, nausea and vomiting, itching, tiredness and pain in the upper-right side of the belly) during treatment. Jinarc must not be used in patients who are anuric (cannot pass urine or have difficulty in passing it), volume depleted (have reduced amounts of fluids in the body) and in patients who cannot perceive or respond to thirst. It must not be used in patients with hypernatraemia (increased sodium levels in the blood) and in patients who are allergic to tolvaptan or medicines that are similar to tolvaptan, so-called benzazepines or their derivatives. Jinarc must also not be used in pregnant and breastfeeding women. For the full list of restrictions, see the package leaflet.

## Why is Jinarc authorised in the EU?

The European Medicines Agency decided that Jinarc's benefits are greater than its risks and that it can be authorised for use in the EU. The Agency noted the unmet need for treatments for autosomal dominant polycystic kidney disease and considered that Jinarc is effective at slowing down cyst formation and possibly the decline in kidney function in patients with the condition. Regarding safety, while the most common side effects are manageable, the Agency identified liver toxicity as the most important risk with Jinarc, which was addressed by putting in place several measures (see below).

## What measures are being taken to ensure the safe and effective use of Jinarc?

The company that markets Jinarc will provide patients and doctors expected to use the medicine with information on the risk of liver toxicity and on the importance of preventing pregnancy during treatment. The company will also carry out a study to further investigate the safety of the medicine, including the risk of liver toxicity, and a study on the effectiveness in patients with severely reduced kidney function.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Jinarc have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Jinarc are continuously monitored. Side effects reported with Jinarc are carefully evaluated and any necessary action taken to protect patients.

## Other information about Jinarc

Jinarc received a marketing authorisation valid throughout the European Union on 27 May 2015.

Jinarc : EPAR - Medicine overview

English (EN) (79.28 KB - PDF)

**First published:** 12/06/2015

**Last updated:** 31/08/2018

[View](/en/documents/overview/jinarc-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (105.66 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/bg/documents/overview/jinarc-epar-medicine-overview_bg.pdf)

español (ES) (77.89 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/es/documents/overview/jinarc-epar-medicine-overview_es.pdf)

čeština (CS) (102.97 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/cs/documents/overview/jinarc-epar-medicine-overview_cs.pdf)

dansk (DA) (76.47 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/da/documents/overview/jinarc-epar-medicine-overview_da.pdf)

Deutsch (DE) (78.77 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/de/documents/overview/jinarc-epar-medicine-overview_de.pdf)

eesti keel (ET) (76.34 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/et/documents/overview/jinarc-epar-medicine-overview_et.pdf)

ελληνικά (EL) (110.63 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/el/documents/overview/jinarc-epar-medicine-overview_el.pdf)

français (FR) (78.63 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/fr/documents/overview/jinarc-epar-medicine-overview_fr.pdf)

hrvatski (HR) (99.06 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/hr/documents/overview/jinarc-epar-medicine-overview_hr.pdf)

italiano (IT) (76.25 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/it/documents/overview/jinarc-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (107.78 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/lv/documents/overview/jinarc-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (102.1 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/lt/documents/overview/jinarc-epar-medicine-overview_lt.pdf)

magyar (HU) (96.98 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/hu/documents/overview/jinarc-epar-medicine-overview_hu.pdf)

Malti (MT) (104.73 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/mt/documents/overview/jinarc-epar-medicine-overview_mt.pdf)

Nederlands (NL) (76.7 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/nl/documents/overview/jinarc-epar-medicine-overview_nl.pdf)

polski (PL) (103.34 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/pl/documents/overview/jinarc-epar-medicine-overview_pl.pdf)

português (PT) (77.67 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/pt/documents/overview/jinarc-epar-medicine-overview_pt.pdf)

română (RO) (100.46 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/ro/documents/overview/jinarc-epar-medicine-overview_ro.pdf)

slovenčina (SK) (102.49 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/sk/documents/overview/jinarc-epar-medicine-overview_sk.pdf)

slovenščina (SL) (97.56 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/sl/documents/overview/jinarc-epar-medicine-overview_sl.pdf)

Suomi (FI) (76.61 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/fi/documents/overview/jinarc-epar-medicine-overview_fi.pdf)

svenska (SV) (77.18 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

31/08/2018

[View](/sv/documents/overview/jinarc-epar-medicine-overview_sv.pdf)

Jinarc : EPAR - Risk management plan

English (EN) (19.93 MB - PDF)

**First published:** 12/06/2015

**Last updated:** 20/11/2024

[View](/en/documents/rmp/jinarc-epar-risk-management-plan_en.pdf)

## Product information

Jinarc : EPAR - Product Information

English (EN) (501.68 KB - PDF)

**First published:** 12/06/2015

**Last updated:** 08/08/2025

[View](/en/documents/product-information/jinarc-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-502)

български (BG) (607.78 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/bg/documents/product-information/jinarc-epar-product-information_bg.pdf)

español (ES) (507.71 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/es/documents/product-information/jinarc-epar-product-information_es.pdf)

čeština (CS) (547 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/cs/documents/product-information/jinarc-epar-product-information_cs.pdf)

dansk (DA) (508.1 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/da/documents/product-information/jinarc-epar-product-information_da.pdf)

Deutsch (DE) (530.81 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/de/documents/product-information/jinarc-epar-product-information_de.pdf)

eesti keel (ET) (536.32 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/et/documents/product-information/jinarc-epar-product-information_et.pdf)

ελληνικά (EL) (589.74 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/el/documents/product-information/jinarc-epar-product-information_el.pdf)

français (FR) (512.33 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/fr/documents/product-information/jinarc-epar-product-information_fr.pdf)

hrvatski (HR) (519.06 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/hr/documents/product-information/jinarc-epar-product-information_hr.pdf)

íslenska (IS) (560.65 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/is/documents/product-information/jinarc-epar-product-information_is.pdf)

italiano (IT) (514.68 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/it/documents/product-information/jinarc-epar-product-information_it.pdf)

latviešu valoda (LV) (533.39 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/lv/documents/product-information/jinarc-epar-product-information_lv.pdf)

lietuvių kalba (LT) (549.36 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/lt/documents/product-information/jinarc-epar-product-information_lt.pdf)

magyar (HU) (598.7 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/hu/documents/product-information/jinarc-epar-product-information_hu.pdf)

Malti (MT) (608.81 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/mt/documents/product-information/jinarc-epar-product-information_mt.pdf)

Nederlands (NL) (497.85 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/nl/documents/product-information/jinarc-epar-product-information_nl.pdf)

norsk (NO) (498.38 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/no/documents/product-information/jinarc-epar-product-information_no.pdf)

polski (PL) (601.54 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/pl/documents/product-information/jinarc-epar-product-information_pl.pdf)

português (PT) (492.07 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/pt/documents/product-information/jinarc-epar-product-information_pt.pdf)

română (RO) (562.21 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/ro/documents/product-information/jinarc-epar-product-information_ro.pdf)

slovenčina (SK) (572.13 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/sk/documents/product-information/jinarc-epar-product-information_sk.pdf)

slovenščina (SL) (547.88 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/sl/documents/product-information/jinarc-epar-product-information_sl.pdf)

Suomi (FI) (503.66 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/fi/documents/product-information/jinarc-epar-product-information_fi.pdf)

svenska (SV) (497.59 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

08/08/2025

[View](/sv/documents/product-information/jinarc-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000286551 07/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Jinarc : EPAR - All Authorised presentations

English (EN) (110.98 KB - PDF)

**First published:** 12/06/2015

**Last updated:** 22/01/2019

[View](/en/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-758)

български (BG) (72.08 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/bg/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_bg.pdf)

español (ES) (35.04 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/es/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_es.pdf)

čeština (CS) (69.78 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/cs/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (33.92 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/da/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (34.8 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/de/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (35.42 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/et/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (71.38 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/el/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_el.pdf)

français (FR) (34.54 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/fr/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (53.4 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/hr/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (34.16 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/is/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_is.pdf)

italiano (IT) (34.64 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/it/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (69.85 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/lv/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (70.88 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/lt/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (50.26 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/hu/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (68.29 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/mt/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (34.82 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/nl/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (34.57 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/no/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_no.pdf)

polski (PL) (50.25 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/pl/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_pl.pdf)

português (PT) (34.51 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/pt/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_pt.pdf)

română (RO) (69.18 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/ro/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (49.9 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/sk/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (49.41 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/sl/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (35.27 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/fi/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (34.49 KB - PDF)

**First published:**

12/06/2015

**Last updated:**

22/01/2019

[View](/sv/documents/all-authorised-presentations/jinarc-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Jinarc Active substance tolvaptan International non-proprietary name (INN) or common name tolvaptan Therapeutic area (MeSH) Polycystic Kidney, Autosomal Dominant Anatomical therapeutic chemical (ATC) code C03XA01

### Pharmacotherapeutic group

Diuretics

### Therapeutic indication

Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.

## Authorisation details

EMA product number EMEA/H/C/002788

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Otsuka Pharmaceutical Netherlands B.V.

Herikerbergweg 292

Opinion adopted 26/02/2015 Marketing authorisation issued 27/05/2015 Revision 24

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Jinarc : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (148.28 KB - PDF)

**First published:** 08/08/2025

[View](/en/documents/procedural-steps-after/jinarc-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Jinarc : EPAR - Procedural steps taken and scientific information after authorisation (archived)

English (EN) (214.54 KB - PDF)

**First published:** 29/09/2016

**Last updated:** 03/04/2025

[View](/en/documents/procedural-steps-after/jinarc-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf)

Jinarc-H-C-PSUSA-00010395-202405 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/21627/2025

English (EN) (132.25 KB - PDF)

**First published:** 03/04/2025

[View](/en/documents/scientific-conclusion/jinarc-h-c-psusa-00010395-202405-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Jinarc-H-C-002788-P46-010 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/158910/2023

English (EN) (4.13 MB - PDF)

**First published:** 18/09/2023

[View](/en/documents/variation-report/jinarc-h-c-002788-p46-010-epar-assessment-report_en.pdf)

Jinarc-H-C-002788-P46-009 : EPAR - Assessment Report

Adopted

Reference Number: EMA/683847/2022

English (EN) (2.15 MB - PDF)

**First published:** 23/08/2022

[View](/en/documents/variation-report/jinarc-h-c-002788-p46-009-epar-assessment-report_en.pdf)

Jinarc-H-C-PSUSA-00010395-201805 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/80619/2018

English (EN) (65.55 KB - PDF)

**First published:** 28/02/2019

[View](/en/documents/scientific-conclusion/jinarc-h-c-psusa-00010395-201805-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Jinarc-H-C-2788-II-0009: EPAR - Assessment Report - Variation

Reference Number: EMA/508732/2018

English (EN) (1.26 MB - PDF)

**First published:** 31/07/2018

**Last updated:** 31/07/2018

[View](/en/documents/variation-report/jinarc-h-c-2788-ii-0009-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Jinarc

Adopted

Reference Number: EMA/CHMP/411942/2018

English (EN) (61.33 KB - PDF)

**First published:** 29/06/2018

**Last updated:** 29/06/2018

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-jinarc_en.pdf)

## Initial marketing authorisation documents

Jinarc : EPAR - Public assessment report

Adopted

Reference Number: EMA/154879/2015

English (EN) (2.17 MB - PDF)

**First published:** 12/06/2015

**Last updated:** 12/06/2015

[View](/en/documents/assessment-report/jinarc-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Jinarc

Adopted

Reference Number: EMA/CHMP/115318/2015

English (EN) (114.73 KB - PDF)

**First published:** 27/02/2015

**Last updated:** 27/02/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-jinarc_en.pdf)

#### News on Jinarc

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 June 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-june-2018) 29/06/2018

[Jinarc recommended for approval in rare kidney disease](/en/news/jinarc-recommended-approval-rare-kidney-disease) 27/02/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 February 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-february-2015) 27/02/2015

#### More information on Jinarc

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu3131175) on 5 August 2013. Jinarc was withdrawn from the Community register of orphan medicinal products in March 2015 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

#### More information on Jinarc

- [A 9-year, Multicentre, Non-interventional, Post-authorisation Safety Study for Patients Prescribed JINARC® for Autosomal Dominant Polycystic Kidney Disease (JINARC PASS) - post-authorisation study](https://catalogues.ema.europa.eu/study/38891)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 08/08/2025

## Share this page

[Back to top](#main-content)